{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:28Z","timestamp":1793672848066,"version":"4.5.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09421-6","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:11:27Z","timestamp":1790230287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2060-9142","authenticated-orcid":false,"given":"Nilufar","family":"Salomova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine G.","family":"Khachatryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7355-637X","authenticated-orcid":false,"given":"Aminjon","family":"Amonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8334-7023","authenticated-orcid":false,"given":"Murodjon","family":"Normatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasiba","family":"Khalmatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-3277","authenticated-orcid":false,"given":"Anvarjon","family":"Rashidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9333-466X","authenticated-orcid":false,"given":"Bekzod","family":"Babamuratov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"1","key":"9421_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","volume":"10","author":"I Boutitah-Benyaich","year":"2025","unstructured":"Boutitah-Benyaich I, Eixarch H, Villacieros-\u00c1lvarez J, Hervera A, Cobo-Calvo \u00c1, Montalban X et al (2025) Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Therapy 10(1):324. https:\/\/doi.org\/10.1038\/s41392-025-02415-4","journal-title":"Signal Transduct Target Therapy"},{"key":"9421_CR2","doi-asserted-by":"publisher","unstructured":"Ferr\u00e8 L, Filippi M, Esposito F (2020) Involvement of Genetic Factors in Multiple Sclerosis. Front Cell Neurosci 14:612953. https:\/\/doi.org\/10.3389\/fncel.2020.612953","DOI":"10.3389\/fncel.2020.612953"},{"issue":"8","key":"9421_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00415-025-13248-0","volume":"272","author":"BK Vitturi","year":"2025","unstructured":"Vitturi BK, Cellerino M, Boccia D, Leray E, Correale J, Dobson R et al (2025) Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis. J Neurol 272(8):513. https:\/\/doi.org\/10.1007\/s00415-025-13248-0","journal-title":"J Neurol"},{"issue":"12","key":"9421_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L (2022) The immunology of multiple sclerosis. Nat Rev Immunol 22(12):734\u2013750. https:\/\/doi.org\/10.1038\/s41577-022-00718-z","journal-title":"Nat Rev Immunol"},{"key":"9421_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1471-4159.1960.tb13448.x","volume":"6","author":"A Lowenthal","year":"1960","unstructured":"Lowenthal A, Vansande M, Karcher D (1960) The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem 6:51\u201356. https:\/\/doi.org\/10.1111\/j.1471-4159.1960.tb13448.x","journal-title":"J Neurochem"},{"issue":"6","key":"9421_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.coi.2011.09.003","volume":"23","author":"H-C von B\u00fcdingen","year":"2011","unstructured":"von B\u00fcdingen H-C, Bar-Or A, Zamvil SS (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 23(6):713\u2013720","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"9421_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"issue":"7","key":"9421_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA (2021) B cells in multiple sclerosis\u2014from targeted depletion to immune reconstitution therapies. Nat Reviews Neurol 17(7):399\u2013414","journal-title":"Nat Reviews Neurol"},{"issue":"3","key":"9421_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA (2024) Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs 84(3):285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w","journal-title":"Drugs"},{"issue":"4","key":"9421_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460\u2013471. https:\/\/doi.org\/10.1002\/ana.21867","journal-title":"Ann Neurol"},{"issue":"8","key":"9421_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S et al (2022) Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 21(8):693\u2013703. https:\/\/doi.org\/10.1016\/s1474-4422(22)00209-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"9421_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2600993","volume":"395","author":"\u00d8 Torkildsen","year":"2026","unstructured":"Torkildsen \u00d8, Brustad Hilde K, H\u00f8gest\u00f8l Einar A, Alstadhaug Karl B, Bhan A, Flemmen Heidi \u00d8 et al (2026) Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. N Engl J Med 395(1):44\u201353. https:\/\/doi.org\/10.1056\/NEJMoa2600993","journal-title":"N Engl J Med"},{"issue":"9","key":"9421_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA (2021) Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs 35(9):985\u2013997","journal-title":"CNS Drugs"},{"issue":"3","key":"9421_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"3","key":"9421_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN, Ocrelizumab (2022) A Review in Multiple Sclerosis. Drugs 82(3):323\u2013334. https:\/\/doi.org\/10.1007\/s40265-022-01672-9","journal-title":"Drugs"},{"issue":"3","key":"9421_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"key":"9421_CR17","doi-asserted-by":"publisher","unstructured":"Banwell B, Kotulska-Jozwiak K, Rost\u00e1sy K, Deiva K, Sato H, Filippi M et al (2025) Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the Phase III OPERETTA 2 study. Paper presented at: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Barcelona, Spain, pp 24\u201326. https:\/\/doi.org\/10.1177\/1352458525137052","DOI":"10.1177\/1352458525137052"},{"issue":"6","key":"9421_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383(6):546\u2013557","journal-title":"N Engl J Med"},{"issue":"3","key":"9421_CR19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S et al (2021) A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler 27(3):420\u2013429. https:\/\/doi.org\/10.1177\/1352458520918375","journal-title":"Mult Scler"},{"issue":"8","key":"9421_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung H-P, Alvarez E, Qian P, Wray S et al (2022) Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 387(8):704\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa2201904","journal-title":"N Engl J Med"},{"issue":"10","key":"9421_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/13543784.2020.1807934","volume":"29","author":"S Torke","year":"2020","unstructured":"Torke S, Weber MS (2020) Inhibition of Bruton\u00b4s tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opin Investig Drugs 29(10):1143\u20131150. https:\/\/doi.org\/10.1080\/13543784.2020.1807934","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"9421_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19(5):289\u2013304. https:\/\/doi.org\/10.1038\/s41582-023-00800-7","journal-title":"Nat Rev Neurol"},{"issue":"4\u20135","key":"9421_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/13524585241234783","volume":"30","author":"X Montalban","year":"2024","unstructured":"Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS et al (2024) Efficacy and safety results after >\u20093.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler 30(4\u20135):558\u2013570. https:\/\/doi.org\/10.1177\/13524585241234783","journal-title":"Mult Scler"},{"issue":"19","key":"9421_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"J Fox Robert","year":"2025","unstructured":"Fox Robert J, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P et al (2025) Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med 392(19):1883\u20131892. https:\/\/doi.org\/10.1056\/NEJMoa2415988","journal-title":"N Engl J Med"},{"issue":"19","key":"9421_CR25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold Douglas L, Cree Bruce AC, Ionete C, Kim Ho J, Sormani Maria P et al (2025) Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 392(19):1893\u20131904. https:\/\/doi.org\/10.1056\/NEJMoa2415985","journal-title":"N Engl J Med"},{"issue":"6","key":"9421_CR26","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","volume":"61","author":"JJ Crawford","year":"2018","unstructured":"Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R et al (2018) Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem 61(6):2227\u20132245. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01712","journal-title":"J Med Chem"},{"issue":"8","key":"9421_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/s1474-4422(25)00174-7","volume":"24","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Dufek M, Budincevic H, Drulovic J, Habek M, Hua LH et al (2025) Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol 24(8):656\u2013666. https:\/\/doi.org\/10.1016\/s1474-4422(25)00174-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"9421_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/ms9.0000000000004298","volume":"88","author":"M Jan","year":"2026","unstructured":"Jan M, Qazi K, Noor A, Naveed M, Khalid M, Waafira A (2026) A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib. Ann Med Surg (Lond) 88(1):974\u2013975. https:\/\/doi.org\/10.1097\/ms9.0000000000004298","journal-title":"Ann Med Surg (Lond)"},{"issue":"7","key":"9421_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491\u2013502. https:\/\/doi.org\/10.1038\/nri2572","journal-title":"Nat Rev Immunol"},{"key":"9421_CR30","doi-asserted-by":"publisher","unstructured":"Li L, Shen S, Shao S, Dang E, Wang G, Fang H et al (2025) The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances. Front Immunol 16:1538555. https:\/\/doi.org\/10.3389\/fimmu.2025.1538555","DOI":"10.3389\/fimmu.2025.1538555"},{"issue":"4","key":"9421_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/09612033221079771","volume":"31","author":"T Liu","year":"2022","unstructured":"Liu T, Neuner R, Thompson A, Pottackal G, Petullo D, Liu J et al (2022) Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective. Lupus 31(4):424\u2013432. https:\/\/doi.org\/10.1177\/09612033221079771","journal-title":"Lupus"},{"issue":"4","key":"9421_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, Hartung HP, Freedman MS, Boyko A, Rad\u00fc EW, Mikol DD et al (2014) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13(4):353\u2013363. https:\/\/doi.org\/10.1016\/s1474-4422(14)70028-6","journal-title":"Lancet Neurol"},{"key":"9421_CR33","doi-asserted-by":"publisher","unstructured":"Silk M, Nantz E (2018) Efficacy and safety of tabalumab in patients with relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled study (P3.397). Neurology 90(15supplement). https:\/\/doi.org\/10.1212\/WNL.90.15_supplement.P3.397","DOI":"10.1212\/WNL.90.15_supplement.P3.397"},{"key":"9421_CR34","doi-asserted-by":"publisher","unstructured":"von Niederh\u00e4usern V, Ruder J, Ghraichy M, Jelcic I, M\u00fcller AM, Schanz U et al (2022) B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 9(6). https:\/\/doi.org\/10.1212\/nxi.0000000000200027","DOI":"10.1212\/nxi.0000000000200027"},{"key":"9421_CR35","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.jaut.2025.103369","volume":"151","author":"V Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, Feinberg D, Webber BR, Moriarity BS et al (2025) CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun 151:103369. https:\/\/doi.org\/10.1016\/j.jaut.2025.103369","journal-title":"J Autoimmun"},{"issue":"23","key":"9421_CR36","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","volume":"188","author":"C Qin","year":"2025","unstructured":"Qin C, Dong M-H, Zhou L-Q, Chu Y-H, Pang X-W, He J-Y et al (2025) Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell 188(23):6414\u20136423. https:\/\/doi.org\/10.1016\/j.cell.2025.09.020","journal-title":"Cell"},{"key":"9421_CR37","doi-asserted-by":"publisher","unstructured":"Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M et al (2024) Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10(4). https:\/\/doi.org\/10.1136\/rmdopen-2024-004727","DOI":"10.1136\/rmdopen-2024-004727"},{"issue":"10","key":"9421_CR38","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"9421_CR39","doi-asserted-by":"publisher","unstructured":"Wen M, Zheng R, Zhang H, Goldberg SY, Jian Z, Gao Y et al (2026) CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy. J Neuroinflammation 23(1). https:\/\/doi.org\/10.1186\/s12974-025-03662-6","DOI":"10.1186\/s12974-025-03662-6"},{"issue":"6","key":"9421_CR40","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awab093","volume":"144","author":"M Mitsdoerffer","year":"2021","unstructured":"Mitsdoerffer M, Di Liberto G, D\u00f6tsch S, Sie C, Wagner I, Pfaller M et al (2021) Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain 144(6):1697\u20131710. https:\/\/doi.org\/10.1093\/brain\/awab093","journal-title":"Brain"},{"key":"9421_CR41","doi-asserted-by":"publisher","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA et al (2023) CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity. Neurol Neuroimmunol Neuroinflamm 10(2). https:\/\/doi.org\/10.1212\/nxi.0000000000200080","DOI":"10.1212\/nxi.0000000000200080"},{"issue":"4","key":"9421_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.stem.2024.03.006","volume":"31","author":"HM Sosnoski","year":"2024","unstructured":"Sosnoski HM, Posey AD Jr. (2024) Therapeutic intersections: Expanding benefits of CD19 CAR T\u00a0cells from cancer to autoimmunity. Cell Stem Cell 31(4):437\u2013438. https:\/\/doi.org\/10.1016\/j.stem.2024.03.006","journal-title":"Cell Stem Cell"},{"issue":"5","key":"9421_CR43","doi-asserted-by":"publisher","first-page":"e200292","DOI":"10.1212\/nxi.0000000000200292","volume":"11","author":"JM Cabrera-Maqueda","year":"2024","unstructured":"Cabrera-Maqueda JM, Sepulveda M, Garc\u00eda RR, Mu\u00f1oz-S\u00e1nchez G, Mart\u00ednez-Cibrian N, Ort\u00edz-Maldonado V et al (2024) CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year. Neurol Neuroimmunol Neuroinflamm 11(5):e200292. https:\/\/doi.org\/10.1212\/nxi.0000000000200292","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Supplement 1","key":"9421_CR44","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1182\/blood-2023-179833","volume":"142","author":"S Damodar","year":"2023","unstructured":"Damodar S, Bhat S, Thirumalairaj R, Malhotra P, Nayak A, Mallya P et al (2023) Hypogammaglobulinemia and Infection Risk in Relapsed Refractory B Cell Malignancy Patients Treated with Varnimcabtagene Autoleucel (IMN-003A), a CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in the Phase-2 Study (IMAGINE). Blood 142(Supplement 1):6853. https:\/\/doi.org\/10.1182\/blood-2023-179833","journal-title":"Blood"},{"issue":"1","key":"9421_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jneuroim.2014.02.003","volume":"270","author":"C de Andr\u00e9s","year":"2014","unstructured":"de Andr\u00e9s C, Tejera-Alhambra M, Alonso B, Valor L, Teijeiro R, Ramos-Medina R et al (2014) New regulatory CD19\u2009+\u2009CD25+ B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids. J Neuroimmunol 270(1):37\u201344. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.02.003","journal-title":"J Neuroimmunol"},{"issue":"2","key":"9421_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3960\/jslrt.56.89","volume":"56","author":"A Tomita","year":"2016","unstructured":"Tomita A (2016) Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. J Clin Exp Hematop 56(2):89\u201399. https:\/\/doi.org\/10.3960\/jslrt.56.89","journal-title":"J Clin Exp Hematop"},{"issue":"1","key":"9421_CR47","doi-asserted-by":"publisher","first-page":"20499","DOI":"10.1038\/s41598-021-00007-0","volume":"11","author":"M Vlaming","year":"2021","unstructured":"Vlaming M, Bilemjian V, Freile J\u00c1, Lourens HJ, van Rooij N, Huls G et al (2021) CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. Sci Rep 11(1):20499. https:\/\/doi.org\/10.1038\/s41598-021-00007-0","journal-title":"Sci Rep"},{"key":"9421_CR48","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","volume":"9","author":"EA Clark","year":"2018","unstructured":"Clark EA, Giltiay NV (2018) CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity. Front Immunol 9:2235. https:\/\/doi.org\/10.3389\/fimmu.2018.02235","journal-title":"Front Immunol"},{"issue":"1","key":"9421_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Luo W, Li C, Mei H (2023) Targeting CD22 for B-cell hematologic malignancies. Exp Hematol Oncol 12(1):90. https:\/\/doi.org\/10.1186\/s40164-023-00454-7","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"9421_CR50","doi-asserted-by":"publisher","first-page":"20637","DOI":"10.1038\/s41598-021-00227-4","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang X, Yu Q, Xu H, Zhou J (2021) Upregulation of CD22 by Chidamide promotes CAR T cells functionality. Sci Rep 11(1):20637. https:\/\/doi.org\/10.1038\/s41598-021-00227-4","journal-title":"Sci Rep"},{"key":"9421_CR51","doi-asserted-by":"publisher","unstructured":"Yuan X, Wang F, Zhao P, Yang B, Yang X, Tian T et al (2025) Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies. Front Immunol 16\u20132025. https:\/\/doi.org\/10.3389\/fimmu.2025.1577360","DOI":"10.3389\/fimmu.2025.1577360"},{"issue":"Supplement 1","key":"9421_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood-2025-813","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Wang X, Chen L, Song J, Sandhu K, Macias A et al (2025) BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed\/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease. Blood 146(Supplement 1):813. https:\/\/doi.org\/10.1182\/blood-2025-813","journal-title":"Blood"},{"issue":"1","key":"9421_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ et al (2022) A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 13(1):217. https:\/\/doi.org\/10.1038\/s41467-021-27853-w","journal-title":"Nat Commun"},{"issue":"16suppl","key":"9421_CR54","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1200\/JCO.2025.43.16_suppl.6523","volume":"43","author":"M Luo","year":"2025","unstructured":"Luo M, Li G, Ding W, Zheng Y, Luo L, Liu J et al (2025) Use of BAFFR CAR-T to treat B cell leukemia\/lymphoma and auto-immune diseases. J Clin Oncol 43(16suppl):6523. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.6523","journal-title":"J Clin Oncol"},{"key":"9421_CR55","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H (2018) BAFF and BAFF-Receptor in B Cell Selection and Survival. Front Immunol 9:2285. https:\/\/doi.org\/10.3389\/fimmu.2018.02285","journal-title":"Front Immunol"},{"issue":"9","key":"9421_CR56","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1177\/09612033231189804","volume":"32","author":"N Sagrero-Fabela","year":"2023","unstructured":"Sagrero-Fabela N, Ort\u00edz-Lazareno PC, Salazar-Camarena DC, Cruz A, Cerpa-Cruz S, Mu\u00f1oz-Valle JF et al (2023) BAFFR expression in circulating T follicular helper (CD4(+)CXCR5(+)PD-1(+)) and T peripheral helper (CD4(+)CXCR5(-)PD-1(+)) cells in systemic lupus erythematosus. Lupus 32(9):1093\u20131104. https:\/\/doi.org\/10.1177\/09612033231189804","journal-title":"Lupus"},{"issue":"Supplement 1","key":"9421_CR57","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2025-1954","volume":"146","author":"P Caimi","year":"2025","unstructured":"Caimi P, Metheny L, Spear M, Liter J, Moriarity B, Webber B (2025) Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Blood 146(Supplement 1):1954. https:\/\/doi.org\/10.1182\/blood-2025-1954","journal-title":"Blood"},{"issue":"1","key":"9421_CR58","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41392-025-02510-6","volume":"10","author":"FS Ismail","year":"2025","unstructured":"Ismail FS, Hartung H-P, Melzer N (2025) Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk. Signal Transduct Target Therapy 10(1):407. https:\/\/doi.org\/10.1038\/s41392-025-02510-6","journal-title":"Signal Transduct Target Therapy"},{"key":"9421_CR59","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.critrevonc.2025.104824","volume":"214","author":"S Wang","year":"2025","unstructured":"Wang S, Li X, Ning H, Wu Y (2025) Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies. Crit Rev Oncol\/Hematol 214:104824. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104824","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"9421_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ekir.2025.10.008","volume":"11","author":"Y Mao","year":"2026","unstructured":"Mao Y, Shen W, Shen J, Zhang C, An K, Tang Y et al (2026) Bicistronic-CD19\/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis. Kidney Int Rep 11(1):53\u201361. https:\/\/doi.org\/10.1016\/j.ekir.2025.10.008","journal-title":"Kidney Int Rep"},{"key":"9421_CR61","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1182\/blood-2025-7639","volume":"146","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Luo L, Ding W, Zeng K, Ma D, Luo M (2025) Development of a novel CD19\/BCMA dual CAR-T for autoimmune diseases. Blood 146:7639. https:\/\/doi.org\/10.1182\/blood-2025-7639","journal-title":"Blood"},{"issue":"6","key":"9421_CR62","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.7150\/ijbs.108036","volume":"21","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Wang M, Zhou R, Deng X, Ouyang X et al (2025) From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy. Int J Biol Sci 21(6):2676\u20132691. https:\/\/doi.org\/10.7150\/ijbs.108036","journal-title":"Int J Biol Sci"},{"issue":"1","key":"9421_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C (2025) CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant 60(1):6\u20139. https:\/\/doi.org\/10.1038\/s41409-024-02429-6","journal-title":"Bone Marrow Transplant"},{"key":"9421_CR64","doi-asserted-by":"publisher","first-page":"1562662","DOI":"10.3389\/fimmu.2025.1562662","volume":"16","author":"A Cheever","year":"2025","unstructured":"Cheever A, Lindsay HG, Kang CC, Hansen M, Demars K, O\u2019Neill KL et al (2025) Chimeric autoantibody receptor T cells specifically eliminate Graves\u2019 Disease autoreactive B cells. Front Immunol 16:1562662. https:\/\/doi.org\/10.3389\/fimmu.2025.1562662","journal-title":"Front Immunol"},{"key":"9421_CR65","doi-asserted-by":"publisher","unstructured":"Segovia MFLD, Defranchi Y, Calder\u00f3n Jofr\u00e9 R, Flores Olivares CA, Keppeke GD (2025) A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes\u2014a brief review. Explor Immunol 5. https:\/\/doi.org\/10.37349\/ei.2025.1003185","DOI":"10.37349\/ei.2025.1003185"},{"issue":"8","key":"9421_CR66","doi-asserted-by":"publisher","first-page":"B18","DOI":"10.1016\/j.jid.2022.05.971","volume":"142","author":"DJ Chang","year":"2022","unstructured":"Chang DJ, Basu S, Micheletti R, Maverakis E, Marinkovich M, Porter DL et al (2022) LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary data. J Invest Dermatology 142(8):B18. https:\/\/doi.org\/10.1016\/j.jid.2022.05.971","journal-title":"J Invest Dermatology"},{"issue":"17","key":"9421_CR67","doi-asserted-by":"publisher","first-page":"eabn1823","DOI":"10.1126\/sciadv.abn1823","volume":"8","author":"M Bronge","year":"2022","unstructured":"Bronge M, H\u00f6gelin KA, Thomas OG, Ruhrmann S, Carvalho-Queiroz C, Nilsson OB et al (2022) Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis. Sci Adv 8(17):eabn1823. https:\/\/doi.org\/10.1126\/sciadv.abn1823","journal-title":"Sci Adv"},{"issue":"6295","key":"9421_CR68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295):179\u2013184. https:\/\/doi.org\/10.1126\/science.aaf6756","journal-title":"Science"},{"key":"9421_CR69","doi-asserted-by":"publisher","first-page":"103495","DOI":"10.1016\/j.jaut.2025.103495","volume":"157","author":"X An","year":"2025","unstructured":"An X, Huang X (2025) Chimeric antigen receptor T cell therapy: a new frontier therapeutic landscape in autoimmune diseases. J Autoimmun 157:103495. https:\/\/doi.org\/10.1016\/j.jaut.2025.103495","journal-title":"J Autoimmun"},{"issue":"6","key":"9421_CR70","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S et al (2024) CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5(6):550. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002. 8.e2","journal-title":"Med"},{"issue":"Supplement 1","key":"9421_CR71","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1182\/blood-2024-205103","volume":"144","author":"J Richter","year":"2024","unstructured":"Richter J, Fischbach F, Pfeffer LK, Fehse B, Berger SC, Reinhardt S et al (2024) CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis. Blood 144(Supplement 1):2073. https:\/\/doi.org\/10.1182\/blood-2024-205103","journal-title":"Blood"},{"key":"9421_CR72","doi-asserted-by":"publisher","first-page":"1388475","DOI":"10.3389\/fonc.2024.1388475","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N (2024) Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol 14:1388475. https:\/\/doi.org\/10.3389\/fonc.2024.1388475","journal-title":"Front Oncol"},{"key":"9421_CR73","doi-asserted-by":"publisher","first-page":"115888","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N (2023) The paths and challenges of off-the-shelf CAR-T cell therapy: An overview of clinical trials. Biomed Pharmacother 169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"9421_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41232-025-00398-x","volume":"45","author":"E Khodabandehloo","year":"2025","unstructured":"Khodabandehloo E, Rayati M, Ahmadi E, Naghdibadi M, Moradi V, Ahmadbeigi N (2025) Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors. Inflamm Regen 45(1):34. https:\/\/doi.org\/10.1186\/s41232-025-00398-x","journal-title":"Inflamm Regen"},{"key":"9421_CR75","doi-asserted-by":"publisher","first-page":"1273507","DOI":"10.3389\/fimmu.2023.1273507","volume":"14","author":"Z Wei","year":"2023","unstructured":"Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L et al (2023) Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol 14:1273507. https:\/\/doi.org\/10.3389\/fimmu.2023.1273507","journal-title":"Front Immunol"},{"key":"9421_CR76","doi-asserted-by":"publisher","unstructured":"Rodero-Romero A, Fern\u00e1ndez-Velasco JI, Monreal E, Sainz-Amo R, \u00c1lvarez-Lafuente R, Comabella M et al (2025) Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis. Front Immunol 16\u20132025. https:\/\/doi.org\/10.3389\/fimmu.2025.1648725","DOI":"10.3389\/fimmu.2025.1648725"},{"key":"9421_CR77","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clicom.2025.09.003","volume":"8","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A (2025) Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases. Clin Immunol Commun 8:60\u201374. https:\/\/doi.org\/10.1016\/j.clicom.2025.09.003","journal-title":"Clin Immunol Commun"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09421-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09421-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09421-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:02:04Z","timestamp":1793671324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09421-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9421"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09421-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI tools were not used in the creation of the work.","order":6,"name":"Ethics","label":"Generative AI declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"806"}}